Hudson Bay Capital Management
MREO

Hudson Bay Capital Management’s Mereo BioPharma MREO Stock Holding History

Hudson Bay Capital Management’s Portfolio MREO Stock Details MREO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-265,000
Closed -$546K – 1421
2025
Q3 		$546K Sell
265,000
-185,000
-41% -$341K ﹤0.01% 909
2025
Q2 		$1.22M Hold
450,000
– – ﹤0.01% 917
2025
Q1 		$1.01M Buy
450,000
+135,000
+43% +$382K ﹤0.01% 923
2024
Q4 		$1.1M Buy
315,000
+140,000
+80% +$550K ﹤0.01% 730
2024
Q3 		$719K Buy
+175,000
New +$724K ﹤0.01% 705

Other funds holding MREO

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Hudson Bay Capital Management's MREO Position: Q4 2025 in Review

Hudson Bay Capital Management sold out of Mereo BioPharma (MREO) in Q4 2025, closing a stake of 265,000 shares — an estimated $546K sold.

Hudson Bay Capital Management first reported a position in MREO in Q3 2024 and held it in 5 quarters. The position peaked at $1.22M in Q2 2025. 70 funds tracked by Wall St. Rank hold MREO as of Q4 2025.

  • Hudson Bay Capital Management reported no remaining Mereo BioPharma position as of Q4 2025 after selling out during the quarter.
  • Hudson Bay Capital Management sold 265,000 Mereo BioPharma shares in Q4 2025, an estimated $546K.
  • Hudson Bay Capital Management first reported a position in Mereo BioPharma in Q3 2024 and held it in 5 quarters.
  • Hudson Bay Capital Management's Mereo BioPharma position peaked at $1.22M in Q2 2025.
  • 70 funds tracked by Wall St. Rank held Mereo BioPharma as of Q4 2025.

Based on Hudson Bay Capital Management's 13F filing for Q4 2025, filed 13 Feb 2026.